Life‐Threatening Acute Tumor Lysis Syndrome With Multiorgan Failure Following First Cycle of Bendamustine–Rituximab in Chronic Lymphocytic Leukemia: A Case Report and Brief Review

Key Points

• This report aims to highlight the risk of tumor lysis syndrome (TLS) following bendamustine-rituximab treatment in chronic lymphocytic leukemia patients with high disease burden.
• Detailed case report of a patient with chronic lymphocytic leukemia
• Observation of symptoms following first cycle of therapy
• Brief literature review on tumor lysis syndrome
• Severe tumor lysis syndrome developed after the first cycle of treatment
• Acute kidney injury and multiorgan failure were observed
• Emphasis on the need for individualized prophylaxis and close monitoring during treatment